These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20449499)

  • 1. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).
    Cano C; Golding BT; Haggerty K; Hardcastle IR; Peacock M; Griffin RJ
    Org Biomol Chem; 2010 Apr; 8(8):1922-8. PubMed ID: 20449499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
    Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
    Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
    Cano C; Barbeau OR; Bailey C; Cockcroft XL; Curtin NJ; Duggan H; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Knights C; Menear KA; Newell DR; Richardson CJ; Smith GC; Spittle B; Griffin RJ
    J Med Chem; 2010 Dec; 53(24):8498-507. PubMed ID: 21080722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.
    Clapham KM; Bardos J; Finlay MR; Golding BT; Griffen EJ; Griffin RJ; Hardcastle IR; Menear KA; Ting A; Turner P; Young GL; Cano C
    Bioorg Med Chem Lett; 2011 Feb; 21(3):966-70. PubMed ID: 21216595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).
    Desage-El Murr M; Cano C; Golding BT; Hardcastle IR; Hummersome M; Frigerio M; Curtin NJ; Menear K; Richardson C; Smith GC; Griffin RJ
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4885-90. PubMed ID: 18678488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors.
    Aristegui SR; El-Murr MD; Golding BT; Griffin RJ; Hardcastle IR
    Org Lett; 2006 Dec; 8(26):5927-9. PubMed ID: 17165896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
    Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
    J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile synthesis of functionalised dibenzothiophenes via Suzuki coupling and microwave-assisted ring closure.
    Rodriguez-Aristegui S; Clapham KM; Barrett L; Cano C; Desage-El Murr M; Griffin RJ; Hardcastle IR; Payne SL; Rennison T; Richardson C; Golding BT
    Org Biomol Chem; 2011 Sep; 9(17):6066-74. PubMed ID: 21748189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
    Leahy JJ; Golding BT; Griffin RJ; Hardcastle IR; Richardson C; Rigoreau L; Smith GC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6083-7. PubMed ID: 15546735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.
    Cano C; Saravanan K; Bailey C; Bardos J; Curtin NJ; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Menear KA; Newell DR; Richardson CJ; Shea K; Smith GC; Thommes P; Ting A; Griffin RJ
    J Med Chem; 2013 Aug; 56(16):6386-401. PubMed ID: 23855836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.
    Ihmaid S; Al-Rawi J; Bradley C; Angove MJ; Robertson MN; Clark RL
    Bioorg Med Chem; 2011 Jul; 19(13):3983-94. PubMed ID: 21664823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.
    Bamborough P; Christopher JA; Cutler GJ; Dickson MC; Mellor GW; Morey JV; Patel CB; Shewchuk LM
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6236-40. PubMed ID: 16997559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.
    Nathan Tumey L; Boschelli DH; Lee J; Chaudhary D
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4420-3. PubMed ID: 18606543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ; Parikh MD
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4882-4. PubMed ID: 19616942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, structure elucidation, DNA-PK, PI3K, anti-platelet and anti-bacteria activity of linear 5, 6, and 10-substituted-2-morpholino-chromen-oxazine-dione and angular 3, 4, 6-substituted-8-morpholino-chromen-oxazine-2,10-dione.
    Morrison R; Al-Rawi JM
    J Enzyme Inhib Med Chem; 2016; 31(sup2):86-95. PubMed ID: 27255290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
    Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
    J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.
    Morrison R; Al-Rawi JM; Jennings IG; Thompson PE; Angove MJ
    Eur J Med Chem; 2016 Mar; 110():326-39. PubMed ID: 26854431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
    Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
    Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.